Funding from the European Community (Horizon program) has been approved for the biomedical research program called ARACHNID (Automated canceR-on-A-CHip orgaN-specific metastatIc spreaD), which will be carried out in collaboration between BIOGENERA’s R&D team and the research group of Prof. Elisa Cimetta of the University of Padua. The research program aims to develop a new, unique […]
Tag: 5
Corporate Update
A New Goal for Biogenera: BGA002, the Future of Cancer Therapy
The Biogenera team has achieved a major breakthrough in the development of the innovative anti-tumor drug BGA002: a revolutionary drug that targets aggressive tumors in both children and adults, specifically targeting cancer cells and sparing healthy ones. An Innovation in the Fight Against Cancer. New scientific data show that BGA002 is able to penetrate and […]
